P3C541b Lipopeptide

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), United Biomedical

Conditions

HIV Infections

Phase 1

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

CompletedNCT00002353

United BiomedicalHIV Infections

Updated: 2005-06-24

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects

CompletedNCT00000845

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 30Updated: 2005-06-24